Medicare Contractor Quickly Retires Draft LCD on Breast Cancer Biomarker Tests Citing New Data | GenomeWeb

NEW YORK (GenomeWeb) – Due to the availability of new data, Medicare contractor Noridian said it will retire a recently issued draft local coverage determination in which it proposed to limit coverage for a number of biomarker tests to guide decisions about adjuvant chemotherapy in breast cancer patients (see pdf below).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.